Peptide LexiconAll compounds

Neuropeptide Y (NPY): The 36-Amino-Acid Brain Peptide, What It Does, and the Two Small Human Trials of a Nasal Dose

Neuropeptide Y is a 36-amino-acid signalling peptide found throughout the brain and the nerves that control blood vessels. It was described in 1982. It is studied for appetite, stress and blood pressure. No medicine containing it is approved; the two published randomised trials of NPY given through the nose enrolled 26 and 30 people, each with single doses.

Endogenous peptideNot approved as a medicineSmall early human trials

Caroline S · Published 2026-11-13

Length

36 amino acids, cut from a 97-residue precursor (UniProt P01303)

Sequence

YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY (human; UniProt P01303, residues 29–64)

Origin

Made by nerve cells in the brain and in the nerves that act on blood vessels; first described in 1982

Last reviewed

2026-11-13

What is it good for?

Neuropeptide Y is a signal the body makes, not a product with an established use. Research links it to appetite, the stress response and the narrowing of blood vessels, mostly from animal work. In people, NPY given through the nose has been tested in a handful of small early studies. Two randomised trials are published: one in 26 people with post-traumatic stress disorder, which found a dose-related effect on one of two anxiety scales, and one in 30 people with depression, which missed its main 48-hour endpoint while showing a difference at 24 hours. Nothing is approved.

Illustration: A clear, empty nasal spray bottle on a white surface with deep green and copper reflections.
Illustration

What it is

Neuropeptide Y is a chain of 36 amino acids used as a signal by nerve cells. UniProt's record for the human gene (P01303, read 2026-11-13) shows a 97-residue precursor: a 28-residue signal piece, then the 36-residue peptide, then a 30-residue leftover called the C-flanking peptide of NPY.

It was first reported in Nature in 1982 by Tatemoto and colleagues, under the title "Neuropeptide Y — a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide" (PMID 6896083). That title names its family: three related 36-residue peptides. The gut member is described in the peptide YY entry.

Property Value Source
Length 36 amino acids UniProt P01303
Human sequence YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY UniProt P01303, residues 29–64
Precursor 97 residues UniProt P01303
First described 1982, as a brain peptide Tatemoto et al., PMID 6896083

A note on the database formula. PubChem's record under the name "neuropeptide Y" (CID 16132350) gives C190H287N55O57 — a formula with no sulfur. The human sequence above contains one methionine, which carries a sulfur atom. So that record cannot be the human peptide; it must describe a form with a different amino acid at that position (our reading of the formula against the sequence, not a statement from PubChem). Molecular weights quoted from that record, about 4,254, are therefore not the human figure.

What it is said to do

Reviews in the field describe NPY as a source of "resilience" against stress, and that word has travelled into wellness writing. The research behind it splits cleanly by species.

Kind of study What was reported Record
Rats, stress model NPY through the nose before or after a stress procedure reduced anxiety-like and depression-like behaviour Serova et al. 2014 (PMID 24326087)
Rats Without stress, no behavioural change a week after one nasal dose; given at the time of stress, it prevented the stress-linked loss of fear extinction Sabban et al. 2023 (PMID 37157881)
Rodents, pain models NPY signalling restrains chronic pain after injury Review, 2025 (PMID 40754889)
People with PTSD Single nasal doses; dose-related effect on one of two anxiety scales Sayed et al. 2018 (PMID 29186416)
People with depression One nasal dose; better than placebo at 24 hours, not at the 48-hour primary endpoint Mathé et al. 2020 (PMID 33009815)

The two human trials, read closely

The PTSD trial (Sayed et al. 2018; registered as NCT01533519) is a dose-ranging safety study, not a test of a treatment.

  • 26 people with post-traumatic stress disorder were randomised; 24 completed both treatment days.
  • Each person received one dose of NPY and one of placebo, a week apart, in random order.
  • Five dose groups of 3 to 6 people each, from 1.4 mg to 9.6 mg — figures reported from the trial, not guidance.
  • NPY "was well tolerated up to and including the highest dose."
  • On the Beck Anxiety Inventory, higher doses were associated with a greater effect favouring NPY (P=.038). On the second scale the abstract reports no significant interaction.

The depression trial (Mathé et al. 2020; EudraCT 2014-000129-19) is the larger of the two.

  • 30 patients with major depressive disorder, all on a stable antidepressant, were randomised: 12 received one 6.8 mg dose of NPY through the nose and 18 received placebo.
  • The planned main result was the change in a depression score at 48 hours. That difference "was not significant."
  • At 24 hours the score had fallen by 10.3 points on NPY and 5.6 on placebo (P=.04) — a difference of 4.7 points by our subtraction. This was a secondary measure.
  • The authors conclude that NPY "is antidepressant, despite not meeting the primary outcome", and call for trials with repeated doses.

Set side by side: one trial positive on one of two scales in groups of six or fewer, the other positive on a secondary time point and negative on its primary one, both after a single dose. That is a signal worth larger trials, and no more. A 2026 review by researchers in this field says the peptide's "therapeutic potential has not yet been realized" (PMID 41818915).

What is registered

ClinicalTrials.gov returned 100 studies mentioning neuropeptide Y and 17 when NPY is searched as an intervention (2026-11-13). Reading those 17, most only measure NPY in blood or tissue. Five give the peptide:

Record What it is Enrolment Status
NCT00748956 Nasal NPY in healthy men 10 Completed
NCT01533519 Dose escalation in PTSD (the trial above) 26 Completed
NCT02639637 NPY as a probe of blood-vessel narrowing 18 Completed
NCT04071600 Nasal NPY in trauma patients 117 planned Status unknown
NCT04838678 NPY as a probe in obesity-related hypertension 100 planned Recruiting

The two largest are a study whose status the registry lists as unknown and one still recruiting; neither has posted results.

What is not established

  • That NPY treats anxiety, PTSD, depression or pain in people. Both patient trials gave a single dose, and the depression trial missed its primary endpoint.
  • Whether repeated dosing is safe or effective. The two published patient trials gave single doses, and the 2020 authors themselves call for repeated-dose trials.
  • How much of a nasal dose reaches the brain in people.
  • Anything about products sold as NPY. Research-vendor listings are not a source for this library.

Where it stands

  • Approved: no.
  • Human trials giving the peptide: five registered, by this entry's reading.
  • Research record: PubMed 6,413 title records; 131 records tagged as randomised controlled trials mention it (2026-11-13).

NPY-producing nerve cells in the hypothalamus are among the targets of ghrelin, the stomach's hunger hormone; a second appetite signal is described in the leptin entry. Another brain peptide tied to appetite and wakefulness is covered in the orexin entry. For peptides marketed for stress and mood, with their evidence set side by side, see the focus-and-mood overview.

What the research shows

Reduces anxiety when given through the nose

Sayed et al. 2018 (PMID 29186416; NCT01533519): 26 people with PTSD randomised, 24 completed, single doses in a cross-over design; higher doses favoured NPY on the Beck Anxiety Inventory (P=.038), with no significant interaction on the second scale

Eases depression when given through the nose

Mathé et al. 2020 (PMID 33009815): 30 patients on an antidepressant, one 6.8 mg dose (12) or placebo (18); better than placebo at 24 hours (P=.04), not significant at the 48-hour primary endpoint

Prevents or reverses stress-related behaviour

Rat studies of intranasal NPY in the single-prolonged-stress model (Serova et al. 2014, PMID 24326087; Sabban et al. 2023, PMID 37157881) — animal only

Relieves chronic pain

A 2025 review (PMID 40754889) built on rodent models of nerve injury and inflammation — animal only

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

No. FDA's drug database returns no application with a neuropeptide as the named active ingredient under this search (openFDA copy dated 2026-11-10; the same search for glucagon returns 12).

Human trials giving NPY

ClinicalTrials.gov returns 17 records for NPY as an intervention; by this entry's reading 5 actually give the peptide, with enrolments of 10, 18, 26, 100 and 117 (2026-11-13).

Published record

PubMed: 6,413 records with 'neuropeptide Y' in the title, 14,967 in title or abstract, 131 tagged as randomised controlled trials (2026-11-13).

Frequently asked questions

What is neuropeptide Y?

A 36-amino-acid signalling peptide made by nerve cells in the brain and in the nerves that control blood vessels. It is usually shortened to NPY.

What does neuropeptide Y do?

Research links it to appetite, the response to stress and the narrowing of blood vessels. Most of that comes from animal experiments; the human evidence is mainly measurements of NPY levels and a few small dosing studies.

Why is it called neuropeptide Y?

Y is the one-letter code for the amino acid tyrosine. The human sequence begins and ends with a tyrosine.

Is there an NPY nasal spray?

Only in research. Two published trials gave single doses — to 26 people with PTSD and to 30 people with depression — and a few other small studies are registered. No NPY product is approved.

Is neuropeptide Y the same as peptide YY?

No. They are related 36-residue peptides, but NPY is made mainly by nerve cells and peptide YY mainly by the gut.

Can neuropeptide Y levels be raised by a supplement?

This entry found no approved product and no trial of a supplement for that purpose. Registered studies that measure NPY look at conditions and treatments, not at supplements that raise it.